We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Okyo Pharma Limited | LSE:OKYO | London | Ordinary Share | GG00BD3FV870 | ORD NPV |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 91.00 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.20 | 1.60 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 91.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 26/11/2024 | 12:00 | UKREG | OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference |
| 30/10/2024 | 11:00 | UKREG | OKYO Pharma to Present at International Tear Film and Ocular Surface.. |
| 23/10/2024 | 11:00 | UKREG | OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to.. |
| 16/10/2024 | 11:00 | UKREG | OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients.. |
| 10/9/2024 | 11:00 | UKREG | OKYO Pharma Announces Chairman Acquires Shares |
| 05/9/2024 | 11:00 | UKREG | OKYO Pharma Announces Chairman Acquires Shares |
| 27/8/2024 | 11:00 | UKREG | OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating.. |
| 23/8/2024 | 13:00 | UKREG | OKYO Pharma CEO Interview to Air on Bloomberg TV |
| 23/8/2024 | 11:00 | UKREG | OKYO Pharma Announces Chairman Acquires Shares |
| 21/8/2024 | 11:00 | UKREG | OKYO Pharma Announces Chairman Acquires Shares |
Okyo Pharma (OKYO) Share Charts1 Year Okyo Pharma Chart |
|
1 Month Okyo Pharma Chart |
Intraday Okyo Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 09/1/2024 | 13:18 | OKYO Pharma PLC | 693 |
| 17/4/2019 | 04:44 | (OKYO) OKYO Pharma Says Data Shows Potential Of Its Dry Eye Treatment | 6 |
| 17/4/2019 | 04:44 | OKYO PHARMA (OKYO) | 14 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 04/4/2023 20:19 by faraweigh2 On NASDAQ maybe tick thwat?NASDAQ will underpin Market Cap and OKYO will indeed go stratospheric. Hardly rocket science ffs.Doh |
Posted at 04/4/2023 14:31 by faraweigh2 lol!!Read the RNS detail as all is quite clear.Onwards and upwards is the way for the Market Cap here at Okyo. Fact. |
Posted at 04/4/2023 07:08 by babbler Not a surprise. UK investors don't get OKYO. |
Posted at 03/4/2023 12:37 by jimduggen They will have to take the share price up here soon. Nasdaq stock is going up 10% a day |
Posted at 01/4/2023 07:46 by faraweigh2 Just look at the 1 and 5 day OKYO trading summary charts on NASDAQ. Awesome! |
Posted at 18/3/2023 17:18 by spkp313703 Hi why is just a big price difference between Nasdaq and LSE share price 2.75 v/s 1.55? |
Posted at 16/3/2023 11:22 by bibs OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website."We are excited to be very close now to moving this drug into its first clinical trial and believe that OK-101 can provide a new way to treat DED patients who are presently not well-served by currently approved drugs" said Gary S. Jacob, Ph.D., CEO of OKYO Pharma Ltd. |
Posted at 13/3/2023 15:49 by bibs Okyo CEO states:"2023 is going to be a big year for us!"Shareholder value to be added here... |
Posted at 13/1/2023 11:23 by faraweigh2 Requoted in part from S/T:OKYO Pharma (OKYO): 2.75p Target 7p A problem with the bear market in small caps is that some timelines have been stretched, as well as valuations kept a lid on until companies are much further down the line as far as their milestones. A good example of both delayed market response and depressed share price is dry eye treatment group OKYO. Of course, it may be the case that even after the latest announcement of clearance of its Investigational New Drug (IND) application from the FDA to initiate a Phase 2 human clinical study. What the market has perhaps still not cottoned onto are a few factors here with OKYO. The dry eye treatment market is a multi-billion dollar one, with the jump in technology with OK-101 which is a treatment, rather than current applications which mere address the symptoms of dry eyes in a mechanical way. Just as important is that because OK-101 is a topical treatment it will have accelerated FDA approval, a point underlined by this month’s news from the company. Such an accelerated approved clearly means that the costs of development are that much more economic. Finally, given the way that the market cap is back to where it was two years ago, despite the advances made, we could see a realignment in 2023, especially given the drug will be “moving into the clinic in the first quarter of 2023"? |
Posted at 17/9/2020 14:55 by dodobird25 Thank you for your reply. I am in total agreement, and I too should have sold when the OKYO share price was listed at around 18p. This has proven to be the case with other pharmaceuticals recently (TILS, SNG to mention two).No more FOMO for me - I have proven it to be a loser's game in the main part. From now on, I shall be selling, when a healthy profit has been achieved, and perhaps buying back if there is a significant pullback. I wish you well with your future investments. Your prediction regarding OKYO, when at its recent peak, has been proven to be correct. We should have a clearer indication as to where this share price is heading next week. I see nothing untoward in my research, but several companies, whose retail shareholders were anticipating significant growth following results, have come unstuck recently. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
